Refreshing results…
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
Download from doi.orgIbrutinib in patients over 80 years old with CLL: a multicenter Italian cohort
Download from doi.orgBTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib
Download from doi.orgShould Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?
Download from doi.orgIbrutinib dose intensity in high‐risk chronic lymphocytic leukemia
UploadMissing publications? Search for publications with a matching author name.